Abstract: The invention features multi-specific protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to a disease antigen, immune checkpoint or signaling molecule.

Abstract: The present disclosure relates generally to methods for treating a patient diagnosed with triple negative breast cancer (TNBC), involving identifying a patient likely to respond to treatment via targeted TGF-? inhibition with an anti-TGF? agent, and treating the subject with the anti-TGF? agent.

Abstract: The present invention further relates to methods for treating a disease of iron metabolism and disease of fat or carbohydrate metabolism using a BMP agonist or antagonist

Abstract: The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.

Abstract: The composition may be used therapeutically or prophylactically and is directed toward a cluster of diarrhea-causing pathogens which cause illness or death in animals, including dogs and cats. It is prepared from a powdered egg preparation and powdered protein matrix, such as bovine colostrum. The eggs are collected from hens which have been immunized with the relevant pathogens or toxins. When the matrix includes colostrum, the powdered colostrum is derived from non-hyperimmune cattle. The vaccination strategy includes the use of antibody cross-reactivity between toxins or pathogens which cause diarrhea. For some diseases, including canine parvo, the clinical improvement using this therapeutic exceeds the standard of care. Instead of a pharmaceutical product, this composition is an orally administered food product with the same safety profile as eggs and milk.

Abstract: The present invention provides a biomaterial that is excellent in scratch resistance and retention in a case of being brought into contact with water. The biomaterial according to the embodiment of the present invention is a biomaterial including a neutral acyl lipid, at least one selected from the group consisting of a phospholipid and a quaternary ammonium salt, and a carboxyvinyl polymer. The neutral acyl lipid includes at least one selected from the group consisting of a neutral monoacyl lipid and a neutral diacyl lipid, and a content of the at least one selected from the group consisting of the neutral monoacyl lipid and the neutral diacyl lipid is 80% by mass to 100% by mass with respect to a total mass of the neutral acyl lipid.

Abstract: The application discloses a functional nucleic acid having nucleoside analog drug integrated into skeleton, a derivative, and preparation methods thereof wherein the derivative is obtained by conjugating or self-assembling the functional nucleic acid having nucleoside analog drug integrated into skeleton with one of a polymer, a hydrophobic molecule, and a transfection reagent. Compared with the prior art, the functional nucleic acid having nucleoside analog drug integrated into skeleton and the derivative thereof can efficiently enter cells and be used to regulate genes; subsequently, the functional nucleic acid having nucleoside analog drug integrated into skeleton can be degraded by nuclease and release active ingredient of the nucleoside analog drug, thus playing a role in chemotherapy.

Abstract: The present disclosure relates generally to bacterial delivery vehicles and their use in efficient transfer of a desired payload into a target bacterial cell of the microbiota of a subject. More specifically, the present disclosure relates to bacterial delivery vehicles with desired host ranges that can be used to efficiently transfer the desired payload in vivo to one or more target bacterial cells of the microbiota of a subject.

Abstract: Nanoparticles formed by emulsion of one or more core polymers, one or more surface altering materials, and one or more low molecular weight emulsifiers have been developed. The particles are made by dissolving the one or more core polymers in an organic solvent, adding the solution of the one or more core polymers to an aqueous solution or suspension of the emulsifier to form an emulsion, and then adding the emulsion to a second solution or suspension of the emulsifier to effect formation of the nanoparticles.

Abstract: Disclosed herein are proteovesicles, referred to herein as a “glypisomes”, that comprise a recombinant glypican polypeptide embedded in a lipid vesicle. Also disclosed is the use of these glypisomes to enhance the activity of growth factors.

Abstract: Oligodeoxynucleotide-based immunostimulatory Toll-Like Receptor 9 (TLR9) agonists are described. Also described are compositions comprising the TLR9 agonists, methods of making the TLR9 agonists, and methods of using the TLR9 agonists to treat immune diseases, disorders or conditions, such as viral infections or cancer.

Abstract: The present invention relates to the field of pharmaceutical preparations, in particular, to a mannose modified targeting nano-preparations, a composition for preparing nano-preparations, a targeting element, a targeting vector, a prepared targeting drug and a preparation method and the application thereof. The described nano-preparations with targeting function is composed of the targeting ligand mannose and its derivatives, nano-preparations and main drug components, and the described targeting material is linked with the spacer material, and then linked with the nano-preparations material to prepare the nano-preparations. The targeting nano-preparations in the present invention has good targetability of mannose receptor, can effectively bond with mannose receptor on target cell. Moreover, the preparation method has universality, can be used for synthesizing a variety of targeting nano-preparations, and is conducive to purification and characterization.

Abstract: A pharmaceutical composition is described, essentially consisting of the paclitaxel prodrug associated with pharmacologically acceptable diluents/excipients, for use in the treatment of non-muscle invasive bladder cancer (NMIBC) by means of intravesical instillations according to a single weekly dose of 600 mg of said prodrug, or two weekly doses equal to a total of 1,200 mg, for 12 or 6 consecutive weeks of treatment. The paclitaxel prodrug used was prepared according to an indirect synthesis process between molecules of hyaluronic acid (HA) and paclitaxel by introducing a spacer (4-bromobutyric acid) between the hyaluronic acid and chemotherapeutic agent.

Abstract: Provided are novel anti-SEZ6 antibodies and antibody drug conjugates, and methods of using such anti-SEZ6 antibodies and antibody drug conjugates to treat cancer.

Abstract: Methods of administering immunoconjugates that bind to CD37 are provided. The methods comprise administering an anti-CD37 immunoconjugate, optionally in combination with an anti-CD20 therapy, to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.

Abstract: A gel formulation has been developed which provides high loading, e.g., between about 5% and about 50% wt/wt agent/total gel weight, of a wide range of agents, especially amine-containing compounds such as local anesthetic agents that are known to be difficult to encapsulate, and which adhere to charged surfaces. Examples of pharmaceutically important amines include anesthetics, such as lidocaine. Tuning the ionic strength of an aqueous medium during preparation, suspension, and dialysis purification of the hydrogel composition allows for retention and/or control of agent loading contents, as well as a high capacity for adhesion to charged surfaces mimicking inflamed tissue. In some instances, the rheological properties of the gel can be tuned such as to impart thixotropic properties to the gels formed.

Abstract: Hypotonic gelling vehicles are used as solubilizing agents for drugs and as a means to provide sustained drug delivery to a mucosal tissue. Solubilizing drugs at higher concentrations enhances drug penetration into the tissues of the body, while the hypotonic gelling vehicle further improves distribution of the drug over a larger surface area for increased absorption and sustained release for reduced side effects and longer duration of action.

Abstract: The present invention relates to novel Toll-like Receptor (TLR) agonist compositions that can demonstrate enhanced innate immune responses, improved stability and lower toxicity than said agonists alone. These immunomodulators comprise one or more TLR agonists linked to glycogen-based nanoparticles. Also provided are processes for manufacturing, and methods of using the compositions to induce therapeutic immune responses.

Abstract: The subject application is directed to a method for treating a mammal harboring a tumor comprising identifying a tumor associated antigen (TAA) expressed by the tumor and parenterally administering to the mammal a therapeutically effective amount of a Sindbis viral vector carrying a gene encoding the TAA to the mammal sufficient to elicit an immune response directed against the tumor, and thereby treating the tumor.

Abstract: The present invention relates to the RRR/SSS pair of enantiomers of the of Gd(PCTA-tris-glutamic glutaric acid), the single enantiomers of the pair, the pharmaceutically acceptable salts thereof, their amide derivatives, and compositions comprising at least 50% of these compounds.

Abstract: The present disclosure provides imaging agents that are useful for the detection and evaluation of heart conditions, such as myocardial infarction. Upon activation, the imaging agents of the present disclosure may be detected using an ultrasound imaging device.

Abstract: New methodologies for site-specifically radiolabeling proteins with the PET isotope [1SF] are required to generate high quality radiotracers for imaging in both the preclinical and clinical settings. The enzymatic radiofluorination overcomes many of the limitations encountered to date with purely chemical approaches. The bacterial enzyme lipoic acid ligase was used to conjugate [18F]-fluorooctanoic acid to both a small peptide and a Fab antibody fragment. Labeling was site-specific and highly efficient under mild aqueous conditions using small amounts of peptide/protein (1-10 nmol). The labeled construct retained full epitope binding affinity and was stable in mouse serum. Using an optimized reaction scheme, mCi quantities of [18F]-Fab were generated, an amount sufficient for human imaging.

Abstract: The invention relates to water soluble 18F-prosthetic groups and the synthesis and use of 18F-labeled biological molecules containing the 18F-prosthetic groups for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.

Abstract: The present invention relates to a method for treating cancer. This method involves providing a first agent comprising a first targeting component coupled to a first cancer therapeutic component and providing a second agent comprising a second targeting component coupled to a second cancer therapeutic component. The first and second targeting components have different biodistributions and/or pharmacokinetics. The first and second agents are administered to a subject having cancer to treat the cancer. Also disclosed is a combination therapeutic comprising the first and second agents.

Abstract: A standalone UV-C sanitizing apparatus and method is provided that is operable to sanitize and disinfect a user's hands or protective gloves. The apparatus includes a housing with light emitting diodes (LEDs) positioned to emit ultraviolet (UV-C) light connected to a circuit board which are individually connected to a power source. The apparatus is configured so that when the user positions the hands or gloves under the housing, the UV-C light is emitted for a predetermined period of time based on the distance to the hands and the power output of the LEDs. The UV-C light is emitted at a wavelength suitable to kill, destroy, or reduce growth of microorganisms/germs. The housing can be configured with a sensor to detect motion under the housing and include a limiter hand guard.

Abstract: The present invention is directed to a non-incinerating medical waste treatment device and methods of use. The device comprising two to four thermal chambers with total independent operation and controls. The desktop mountable device contains electronic, electromechanical, and made-up mechanical assemblies. The intended application of the device and method is for sterilizing medical waste such as bacterial and viral biological contaminated red bag and/or sharps in order to facilitate safe handling and disposal.

Abstract: The present invention relates to liquid filled light distributor comprising an elongated tubular body with a tube wall defining an in inner lumen filled with a liquid, said tubular body having a proximal end closed by first closing means a distal end closed by second closing means Wherein the proximal end is arranged to be in optical communication with a light source and wherein the refractive index of the tube wall is n1 and the refractive index of the fluid is n2 and n1/n2<1 so that light from the light source travels along the longitudinal direction of the tubular body and that a part of the light is emitted through the tube wall along at least a part of the tubular body. Further a method of use for the liquid filled light distributor is provided.

Abstract: A disinfectant transmissive material incorporated into a case for a mobile device or a supporting surface of a disinfecting charger to enable disinfection of hard to reach areas. The case can be self-disinfecting. The disinfecting charger can have monitoring and safety systems that detect proximity and provide user feedback on safety, disinfection, and charge status along with automatic interlocks to protect the user from overexposure to disinfectant.

Abstract: The present disclosure is generally related to devices, methods and systems for cleaning, disinfecting and/or sterilizing a medical device, medical hoses and tubes and accessories thereof with ozone gas, in particular the disclosure relates to devices, methods and systems with multiple receptacles for providing closed-loop fluid pathways to distribute ozone gas to inner passageways and the outer compartments of medical devices. The devices in accordance with an embodiment of the disclosure have two or more receptacles for distributing ozone gas, a gas-tight compartment, an ozone operating system, and one or more connector units configured to fluidly migrate ozone in closed-loop treatment systems.

Abstract: Technologies for sanitizing medical devices are described. In particular, sanitizing systems, components of sanitizing systems, and methods for sanitizing medical devices such as continuous positive airway pressure (CPAP) equipment are described. In embodiments, the sanitizing systems include a sanitizing gas generator and a base including at least one exhaust port and a filter.

Abstract: An air treatment system includes a pathogen treatment chamber that is configured with one or more channel assemblies such that air passing therethrough is treated with ultraviolet (UV) light. A channel assembly includes multiple parallel channels configured between the opposed ends of the channel assembly. One end of each channel is configured with an ultraviolet (UV) light source exhibiting a first wavelength, while the remaining end of each channel is configured with an ultraviolet (UV) light source exhibiting a second wavelength. A removable light source module including the UV light sources exhibiting the first wavelength spans one of the opposed ends of the channels, while another removable UV light source module including the UV light sources exhibiting the second wavelength spans the remaining opposed ends of the channels.

Abstract: An electrospray ionization olfactometer device, method and system for vaporizing aroma compounds for the purpose of psychophysical experimentation and sensory evaluation are provided.

Abstract: A flexible ion generator device that includes a dielectric layer having a first end, a second end, a first side, a second side, a top side, and a bottom side, at least one trace positioned on the dielectric layer and having a plurality of emitters engaged to the at least one trace. A plurality of lights disposed on the dielectric layer.

Abstract: A biomedical implant (16, 18) is formed from magnesium (Mg) single crystal (10). The biomedical implant (16, 18) may be biodegradable. The biomedical implant (16, 18) may be post treated to control the mechanical properties and/or corrosion rate thereof said Mg single crystal (10) without changing the chemical composition thereof. A method of making a Mg single crystal (10) for biomedical applications includes filling a single crucible (12) with more than one chamber with polycrystalline Mg, melting at least a portion of said polycrystalline Mg, and forming more than one Mg single crystal (10) using directional solidification.

Abstract: A new insight on the lubrication of joints is presented. Addition of small amounts of nanoscale diamond particles to a joint promotes a substantial improvement in friction and wear behavior of the joint surfaces. The joints can be artificial or natural joints.

Abstract: The invention provides a method for preparing an expanded cell or tissue sample suitable for microscopic analysis. Expanding the sample can be achieved by binding, e.g., anchoring, key biomolecules to a DMAA-TF polymer network and swelling, or expanding, the polymer network, thereby moving the biomolecules apart as further described herein. As the biomolecules are anchored to the polymer network isotropic expansion of the polymer network retains the spatial orientation of the biomolecules resulting in an expanded, or enlarged, sample.

Abstract: The device is intended for the noninvasive induction of dynamic deformation of body tissue to differentiate tissue cells. It comprises the following components: (i) a suspension of particles suspended in solution; and (ii) an external actuator which is capable of magnetically, electrically, vibrationally, or thermally stimulating the suspended particles.

Abstract: The present invention relates to pliable, compression-resistant bone-based products and methods of making the same.

Abstract: Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that include a plurality of particulate structures. The particulate structures further include an acellular ECM core and an outer layer or coating comprising poly(glycerol sebacate) (PGS) and everolimus. When the particulate structures are delivered to the damaged cardiovascular tissue the outer layer is adapted to induce a first level of remodeling and suppress hyperplasia, and the acellular ECM is adapted to induce a second level of remodeling.

Abstract: The present invention relates to a peripheral nerve-specific hydrogel material, which is deliverable in a minimally invasive fashion, sustains the growth of neurons, and speeds recovery following surgical reconstruction.

Abstract: The present invention provides a method for producing regenerated hair follicle primordium that allows production of regenerated hair follicle primordium more easily and in larger amounts compared to conventional production methods. A method for producing regenerated hair follicle primordium comprising a step of obtaining hair follicle primordium by culturing a first population of cells comprising epithelial cells and a second population of cells comprising mesenchymal cells while allowing them to be in contact is provided. The production method of the present invention is characterized in that at least either one of said first population of cells and said second population of cells has formed cell aggregates before said contact, and a culture support is not used when contacting the other population of cells with said cell aggregate.

Abstract: A composite material in one of embodiments includes a crystal phase of titanium fluoride and a metal crystal phase of titanium. The crystal phase of the titanium fluoride is present in a first region located away from a surface in a depth direction.

Abstract: A hydrogel material for the treatment of stroke or other brain injury includes a collection of hyaluronic acid-based microgel particles comprising one or more network crosslinker components, wherein the hyaluronic acid-based microgel particles, when exposed to an endogenous annealing agent (e.g., Factor XIIIa), links the hyaluronic acid-based microgel particles together in situ to form a covalently-stabilized scaffold of microgel particles having interstitial spaces therein. The hydrogel material may be injected into a stroke cavity and was shown to promote brain tissue repair by promoting the recruitment of neural stem cells to the injured site and reducing the post-stroke inflammatory response.

Abstract: A biocompatible and bioresorbable implantable device that is intended to be deployed in the middle meningeal artery through intra-arterial catheters and release an anesthetic agent for a prolonged period into the branches of the middle meningeal artery to treat severe headaches including migraine and trigeminal neuralgias. The implantable device may be a mesh with multiple helical loops, fenestrated collapsible hollow shell or spheroid, or folded sheath.

Abstract: A device for collecting and processing bone fragments comprises a housing and a filter element disposed in the housing. The filter element at least partially defines a collection chamber for the collection of a composition comprising bone fragments. An inlet cap is releasably coupled to either the housing or to the filter element and configured to receive the composition. The inlet cap includes a body, an inlet port extending from the body and configured to be coupled to a surgical tool, and a spout extending from the body opposite the inlet port. The spout includes an injection port extending into the collection chamber of the filter element. A outlet cap is releasably coupled to the housing and is configured to be coupled to a vacuum source.

Abstract: Fluid collection systems having a canister, a lid, and a liner assembly are described. The liner assembly may include a liner and a fitment assembly. The fitment assembly may be connected to the liner by a gland. The fitment assembly may be held in place by at least one of any number of features, including a bracket or other fitment support connected to the canister and/or the lid, supports integrated into the fitment itself, a snapping mechanism, or a notch in one or more of the canister and the lid that supports the fitment.

Abstract: A filter adaptor includes a body that defines an internal passageway disposed between an inlet and an outlet, the passageway configured to permit passage of a fluid in a first direction defined by the inlet and the outlet; and a filter disposed within the passageway and oriented to define a volumetric direction that is different than the first direction. Another filter adaptor includes a body that defines an internal passageway disposed between an inlet and an outlet, and a filter disposed within the passageway, wherein the filter comprises a gelling absorbent material that, when in a dry state, is permeable to gas and that, when contacted by an aqueous fluid, converts to a gel. Such filter adaptors may be used for negative pressure wound therapy, dressing, or as syringe filters.

Abstract: A system, method, and apparatus for treating a tissue site with reduced pressure includes a dressing adapted to be positioned proximate the tissue site. An absorbent may be adapted to be fluidly coupled to the manifold, and an ion exchange member may be adapted to be fluidly coupled between the manifold and the absorbent. A sealing member may be adapted to cover the tissue site to form a sealed space having the manifold disposed therein. A reduced-pressure source may be adapted to be fluidly coupled to the manifold.

Abstract: Embodiments of negative pressure wound therapy systems and methods for operating the systems are disclosed. In one embodiment, an apparatus includes a housing, as well as a pressure source, controller, and output device supported by the housing. The pressure source couples via a fluid flow path to a wound dressing and provides negative pressure to the wound dressing. The controller operates the pressure source to provide negative pressure to the wound dressing. The output device provides identification data to an electronic device, and the identification data is usable by the electronic device to access a label associated with the housing or one or more components supported by the housing.

Abstract: Negative pressure wound therapy apparatuses and dressings, and systems and methods for operating such apparatuses for use with dressings are disclosed. In some embodiments, controlling the delivery of therapy can be based on monitoring and detecting various operating conditions. An apparatus can have a controller configured to monitor a duty cycle of a source of negative pressure. Based on the monitored duty cycle, the controller can determine whether a leak is present and provide an indication to a user. The controller can determine a duty cycle threshold in order to achieve an optimal or near optimal balance between an uninterrupted delivery of therapy, avoidance inconveniencing a user, conserving power, achieving optimal or near optimal efficiency, and/or limiting vibrational noise. In some embodiments, the duty cycle threshold is determined based at least in part on a capacity of a power source and an operational time of the apparatus.